1. Home
  2. BGI vs AIMD Comparison

BGI vs AIMD Comparison

Compare BGI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

HOLD

Current Price

$0.68

Market Cap

15.9M

Sector

N/A

ML Signal

HOLD

AIMD

Ainos Inc.

HOLD

Current Price

$1.71

Market Cap

13.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGI
AIMD
Founded
1879
1984
Country
Canada
United States
Employees
N/A
41
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
13.1M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
BGI
AIMD
Price
$0.68
$1.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.5K
22.3K
Earning Date
12-05-2025
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.44
52 Week High
$1.57
$4.50

Technical Indicators

Market Signals
Indicator
BGI
AIMD
Relative Strength Index (RSI) 40.35 53.18
Support Level $0.64 $1.63
Resistance Level $0.78 $1.84
Average True Range (ATR) 0.06 0.10
MACD -0.01 -0.01
Stochastic Oscillator 25.20 30.36

Price Performance

Historical Comparison
BGI
AIMD

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: